These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16027519)

  • 1. Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer.
    Bruce IA; Slevin NJ; Homer JJ; McGown AT; Ward TH
    Anticancer Drugs; 2005 Aug; 16(7):719-26. PubMed ID: 16027519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC.
    Schultz JD; Rotunno S; Erben P; Sommer JU; Anders C; Stern-Straeter J; Hofheinz RD; Hörmann K; Sauter A
    Oncol Rep; 2011 Apr; 25(4):1145-51. PubMed ID: 21249321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics.
    Wietrzyk J; Milczarek M; Kutner A
    Oncol Res; 2007; 16(11):517-25. PubMed ID: 18306931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
    Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
    Kłosowska-Wardęga A; Hasumi Y; Åhgren A; Heldin CH; Hellberg C
    Melanoma Res; 2011 Feb; 21(1):57-65. PubMed ID: 20975605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C; Aderhold C; Faber A; Sauter A; Hofheinz RD; Stern-Straeter J; Hoermann K; Schultz JD
    Oncol Rep; 2014 Aug; 32(2):668-76. PubMed ID: 24890748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
    Bertino P; Piccardi F; Porta C; Favoni R; Cilli M; Mutti L; Gaudino G
    Clin Cancer Res; 2008 Jan; 14(2):541-8. PubMed ID: 18223230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
    Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM; Saigal B; Donato NJ
    J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
    Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
    Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.
    Lin CH; Yen RF; Jeng YM; Tzen CY; Hsu C; Hong RL
    Head Neck; 2005 Dec; 27(12):1022-7. PubMed ID: 16265655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.
    Hayes KE; Walk EL; Ammer AG; Kelley LC; Martin KH; Weed SA
    Oncogene; 2013 Oct; 32(40):4766-77. PubMed ID: 23146907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A
    Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.